BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, May 1, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 19, 2019
View Archived Issues
NTHL1 mutations lead to tumor predisposition syndrome
Read More
Drop the MIC? At least add to it
Read More
AAAS Annual Meeting: Science is there to make universal flu vaccine; money to follow?
Read More
Afibromer shielded engineered allogeneic cells demonstrate safety and efficacy in hemophilia A model
Read More
FAK as a potential new target in triple-negative breast cancer
Read More
CMG-002 overcomes chemoresistance in preclinical models of ovarian cancer
Read More
Bayer and Evotec present the discovery of BAY-293
Read More
GPR39 agonist reduces alcohol intake in mouse model of alcohol use disorder
Read More
Melittin-nanoparticles target liver sinusoidal endothelial cells and suppress liver metastasis
Read More
Enrollment underway in phase I study of J-147
Read More
Otsuka Pharmaceutical initiates two phase III trials of centanafadine in adults with ADHD
Read More
Human parthenogenetic stem cell therapy improves experimental traumatic brain injury deficits
Read More
Novartis discloses new FOXO3 inhibitors and RAC activators
Read More
WuXi AppTec and BioLingus establish sublingual drug delivery collaboration
Read More
Merck & Co. divulges IDO1 inhibitors
Read More
Saniona reports data from second part of phase IIa study of Tesomet in Prader-Willi syndrome
Read More
FASST study of lanifibranor in diffuse cutaneous systemic sclerosis does not meet primary endpoint
Read More
Keimyung University presents HSP90 inhibitors
Read More
Takeda Pharmaceutical identifies orexin OX2 receptor agonists
Read More
FronThera US Pharmaceuticals describes PI3K inhibitors
Read More
Grant supports NovaBiotics' development of Novamycin
Read More
Phase III topline results for tanezumab in chronic low back pain
Read More
Phase III REGENERATE study of OCA in liver fibrosis due to NASH achieves primary endpoint
Read More
Topline results from Japanese confirmatory phase III study of ONO-5704 in knee osteoarthritis
Read More
